Prospective clinical study of comprehensive genomic profiling for patients with chemotherapy-naive advanced cancer.

Prospective clinical study of comprehensive genomic profiling for patients with chemotherapy-naive advanced cancer. - FIRST-Dx trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042408

Enrollment

180

Registered

2020-11-11

Start date

2021-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age>20 y.o. ECOG PS 0-1 Pathologically confirmed malignancy Cancers in GI tracts, biliary tract, pancreas, lung, breast, gynecologic organs, and skin melanoma. No prior chemotherapy or radiotherapy. Tissue available for F1CDx Written informed consent

Exclusion criteria

Exclusion criteria: Inappropriate for trial due to mental disease. Inappropriate for trial judged by medical doctors.

Design outcomes

Primary

Measure	Time frame
Ratio of cancer patients with actionable genomic alteration	—

Countries

Japan

Contacts

Public ContactJunichi Matsubara

Kyoto University Hospital Department of Clinical Oncology

jmatsuba@kuhp.kyoto-u.ac.jp075-751-3111

Outcome results